Aentrek (Entrectinib) is approved for the treatment of adult metastatic ROS1-positive non-small cell lung cancer. It is also approved for use in adults and children aged 12 years and older with NTRK gene fusion-positive solid tumors, including those that have metastasized, where surgery may result in high risk of recurrence, have progressed after previous treatments or have no comparable alternative therapy.

 Aentrek (Entrectinib)  is a tyrosine kinase inhibitor that acts on several receptors, including (TRK) TRKA, TRKB,TRKCROS1(ALK). These receptors signal downstream through pathways such as mitogen activated protein kinases, phosphatidylinositol 3-kinases, and phosphatidylinositol phosphatase C-γ to promote cell proliferation. Entrectinib inhibits these signaling pathways, thereby inhibiting tumor growth and altering the balance towards apoptosis, resulting in a reduction in tumor size.

 The recommended dose of Entrectinib is 600 mg daily, taken orally in one capsule. Do not open, crush, chew or dissolve the capsule contents.